LAKE FOREST, Ill., Oct. 13 /PRNewswire-FirstCall/ — Hospira, Inc. , a global specialty pharmaceutical and medication delivery company, announced today that it has acquired the EndoTool(R) business from MD Scientific, LLC. The EndoTool glucose management system, a highly sophisticated software system cleared by the U.S. Food and Drug Administration (FDA), helps establish and maintain glycemic control in acute, critical care and operating room settings by calculating the dose of intravenous (I.V.) insulin needed to effectively control blood glucose levels. Hospira is demonstrating EndoTool at the American Nurses’ Credentialing Center (ANCC) National Magnet Conference, Oct. 15 – 17, in Salt Lake City.
“This acquisition represents an important extension of Hospira’s commitment to improved outcomes, patient safety and enhanced clinician efficiency,” said Chris Kolber, president, Global Devices, Hospira. “With the market-leading EndoTool in the Hospira portfolio, we are underscoring our commitment to technological leadership in the important area of clinical-decision support systems.”
Traditionally, nurses and other clinicians use paper-based protocols to manually monitor and adjust I.V. insulin dosing. The EndoTool software system is easy to operate, runs on a hospital’s existing computer system and can interface with a hospital information system (HIS).
EndoTool actively models and adapts to individual patient responses to I.V. insulin to help manage current and predict future dosage levels. It is the only software that uses five separate data points — based on the patient’s most recent blood glucose readings — to provide personalized, safe and effective glycemic control. Integrating more than 30 unique algorithms (mathematical steps) into its dosage calculation method, EndoTool helps ensure an extremely low incidence of hypoglycemia (low blood glucose) by automating and standardizing the practice of glucose management.
“After using EndoTool in one of our hospitals as a pilot, we observed better and safer glucose control and improved patient outcomes,” said Loran Hauck, M.D., senior vice president and chief medical officer, at Florida-based Adventist Health System. “We then moved to install EndoTool in the ICUs at every hospital in our system. In the future we plan to use EndoTool in the operating rooms, emergency department, obstetrical units and step-down units across our ten-state, 37-hospital health system.”
To date, more than 10,000 patients with more than 450,000 blood glucose readings have had their blood glucose levels controlled with EndoTool.
In acute and critical-care settings, effective blood glucose management is integral to high-quality, safe patient care. Maintaining the appropriate precision to avoid under-or over-dosing of insulin is essential to improved patient management. For example, overly aggressive insulin therapy can increase the risk of hypoglycemia, which is an independent risk factor for mortality.(1,2) Whereas, complications of hyperglycemia (high blood glucose) include increased morbidity and mortality; as well as increased risk of secondary infection, impaired immune function and delayed wound healing.(1,3,4)
The EndoTool customer base includes leading healthcare institutions in both community and academic settings, including many Magnet accredited hospitals. Magnet status is given by the ANCC, an affiliate of the American Nurses Association, to hospitals that satisfy a set of criteria designed to measure the strength and quality of their nursing.
As part of the agreement, Hospira acquired additional assets related to the EndoTool business, including the MD Scientific headquarters in Charlotte, N.C., and the employees supporting the product. Financial details of the agreement were not disclosed.
About MD Scientific
MD Scientific, LLC, headquartered in Charlotte, N.C., was formed in 2003 with the mission of introducing physician innovation to improve healthcare.
About Hospira
Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has more than 14,000 employees. Learn more at http://www.hospira.com/.
Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Hospira cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Hospira’s operations and may cause actual results to be materially different from expectations include the risks, uncertainties and factors discussed under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Hospira’s latest Annual Report on Form 10-K, and Hospira’s subsequent Quarterly Reports on Form 10-Q, which are filed with the Securities and Exchange Commission, and incorporated by reference. Hospira undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.
(1) Van den Berghe G, et al. N Engl J Med 2006;354:449-61. (2) Krinsley JS, et al. Crit Care Med 2007;35:2262-7. (3) Van den Berghe G, et al. N Engl J Med 2001;345:1359-67. (4) Inzucchi SE, et al. N Engl J Med 2006;355:1903-11.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20040503/HSPLOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, [email protected]
Hospira, Inc.
CONTACT: Media, Tareta Adams, +1-224-212-2535, or Financial Community,Karen King, +1-224-212-3323, both of Hospira, Inc.
Web site: http://www.hospira.com/
Comments